Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate

Hepatology

Volumn 62, Issue 2, 2015, Pages 496-504

  Udali, Silvia ^a   Guarini, Patrizia ^a   Moruzzi, Sara ^a   Ruzzenente, Andrea ^a   Tammen, Stephanie A ^b   Guglielmi, Alfredo ^a   Conci, Simone ^a   Pattini, Patrizia ^a   Olivieri, Oliviero ^a   Corrocher, Roberto ^a   Choi, Sang Woon ^b,c   Friso, Simonetta ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b TUFTS UNIVERSITY   (United States)

^c CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; DNA;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYDROXYMETHYLATION; DNA METHYLATION; EPIGENETICS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFE EXPECTANCY; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TISSUE LEVEL; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LIVER RESECTION; METHYLATION; MORTALITY; NONPARAMETRIC TEST; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; METHYLATION; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 84938215318     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27823     Document Type: Article

References (48)

1. Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 2013;502:472-479.
2. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447:433-440.
3. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001;293:1068-1070.
4. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010;28:1057-1068.
5. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-692.
6. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 2006;310:251-274.
7. Ehrlich M, Lacey M. DNA hypomethylation and hemimethylation in cancer. Adv Exp Med Biol 2013;754:31-56.
8. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007;1775:138-162.
9. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-153.
10. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
11. Munzel M, Globisch D, Carell T. 5-Hydroxymethylcytosine, the sixth base of the genome. Angew Chem Int Ed Engl 2011;50:6460-6468.
12. Wyatt GR, Cohen SS. A new pyrimidine base from bacteriophage nucleic acids. Nature 1952;170:1072-1073.
13. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009;324:929-930.
14. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-935.
15. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011;333:1300-1303.
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
17. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States. Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009;136:1134-1144.
18. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44:239-245.
19. Cardinale V, Bragazzi MC, Carpino G, Torrice A, Fraveto A, Gentile R, et al. Cholangiocarcinoma: increasing burden of classifications. Hepatobiliary Surg Nutr 2013;2:272-280.
20. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005;128:1655-1667.
21. Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012;55:1799-1808.
22. Ma L, Chua MS, Andrisani O, So S. Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol 2014;20:333-345.
23. Sceusi EL, Loose DS, Wray CJ. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford) 2011;13:369-376.
24. Huang L, Frampton G, Liang LJ, Demorrow S. Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol 2011;1:23-29.
25. Stutes M, Tran S, DeMorrow S. Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs. World J Gastroenterol 2007;13:6465-6469.
26. Goeppert B, Konermann C, Schmidt CR, Bogatyrova O, Geiselhart L, Ernst C, et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology 2014;59:544-554.
27. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013;32:3091-3100.
28. Chen ML, Shen F, Huang W, Qi JH, Wang Y, Feng YQ, et al. Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry. Clin Chem 2013;59:824-832.
29. Friso S, Udali S, Guarini P, Pellegrini C, Pattini P, Moruzzi S, et al. Global DNA hypomethylation in peripheral blood mononuclear cells as a biomarker of cancer risk. Cancer Epidemiol Biomarkers Prev 2013;22:348-355.
30. Friso S, Choi SW, Dolnikowski GG, Selhub J. A method to assess genomic DNA methylation using high-performance liquid chromatography/electrospray ionization mass spectrometry. Anal Chem 2002;74:4526-4531.
31. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, et al. A common mutation in the 5, 10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99:5606-5611.
32. Tammen SA, Dolnikowski GG, Ausman LM, Liu Z, Sauer J, Friso S, et al. Aging and alcohol interact to alter hepatic DNA hydroxymethylation. Alcohol Clin Exp Res 2014;38:2178-2185.
33. Nestor CE, Reddington JP, Benson M, Meehan RR. Investigating 5-hydroxymethylcytosine (5hmC): the state of the art. Methods Mol Biol 2014;1094:243-258.
34. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001;61:4238-4243.
35. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-2722.
36. Nishida N, Kudo M, Nishimura T, Arizumi T, Takita M, Kitai S, et al. Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma. PLoS One 2013;8:e72312.
37. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 2001;33:561-568.
38. Lee HS, Kim BH, Cho NY, Yoo EJ, Choi M, Shin SH, et al. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res 2009;15:812-820.
39. Kim BH, Cho NY, Shin SH, Kwon HJ, Jang JJ, Kang GH. CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma. Virchows Arch 2009;455:343-351.
40. Nakanuma Y, Sasaki M, Ikeda H, Sato Y, Zen Y, Kosaka K, et al. Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis. Hepatol Res 2008;38:325-334.
41. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012;122:2911-2915.
42. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest 2012;122:3914-3918.
43. Liu C, Liu L, Chen X, Shen J, Shan J, Xu Y, et al. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One 2013;8:e62828.
44. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011;2:627-637.
45. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013;32:663-669.
46. Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 2011;71:7360-7365.
47. Pfeifer GP, Kadam S, Jin SG. 5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin 2013;6:10.
48. Nestor CE, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Dunican D, et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res 2011;22:467-477.